Clopidogrel is an antiplatelet substance that prevents blood coagulation in the arteries. It is an inactive pro drug that becomes activated after first-pass metabolism by the liver. The active metabolite of Clopidogrel is 2-oxoClopidogrel, which is unstable therefore pharmacokinetic data is obtained by measuring the inactive metabolite Clopidogrel acid in plasma. Clopidogrel is taken orally in tablet form. The aim of this project was to develop a LC-MS/MS method for quantification of Clopidogrel and its metabolite in plasma. The method has been developed by optimizing the sample preparation.

Introduktion: Akut hjärtinfarkt är en vanlig dödsorsak. Viktigaste behandlingsinsatsen vid hjärtinfarkt är att snabbt öppna det ockluderade kranskärlet genom primär Perkutan Coronar Intervention (PCI). Viktigt är även att behandlingen förhindrar att kärlet åter ockluderar. Detta görs genom att behandla med det blodproppshämmande och kärlpåverkande läkemedlet Clopidogrel. Enligt en ny behandlingsrutin ges Clopidogrel redan i ambulansen vid konstaterande av hjärtinfarkt för att uppnå effekt så fort som möjligt.

Several diseases increase the risk of thrombosis in dogs and cats, often with a fatal outcome. Currently there are no definite treatment guidelines for the use of thrombolytic and thromboprofylactic agents in veterinary medicine. None of these drugs are approved for dogs and cats in Sweden. Medicines aimed for humans have been used tentatively. This literature study is an investigation of what is currently known about the effects and safety of these pharmacological agents when used for dogs and cats.